phosphatidylethanolamine binding protein 1 pseudogene 2Genealiases: []
Q-omics provides the consensus-scored PEBP1P2 profile across patient tissues and cancer cell-line models. PEBP1P2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PEBP1P2 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, PEBP1P2 RNA expression shows 14,890 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, KIRP, and ACC as cancer lineages where PEBP1P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PEBP1P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PEBP1P2 survival associations across molecular data types. PEBP1P2 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PEBP1P2 RNA expression–survival associations across cancer types. High PEBP1P2 expression shows unfavorable associations in COAD and MESO, but favorable associations in KIRC, KIRP, THYM and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PEBP1P2 RNA expression.
This table summarizes PEBP1P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for PEBP1P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PEBP1P2 shows lower tumor expression in KIRP, THCA, KIRC, KICH, BRCA and BLCA. The KIRP box plot shows higher PEBP1P2 RNA expression in normal versus tumor tissue (log2 FC = −0.687, t-test p < 0.001).
This table shows molecular features associated with PEBP1P2 in patient tissues and cancer cell lines. In patient samples, PEBP1P2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
